SHARONBIO

SHARONBIO:The Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 09-Jan-2019, regarding that�� Ms. Komal Mota has been appointed as a Company Secretary & Compliance Officer w.e.f�� January 08, 2019." On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment)The response of the Company is awaited.

Sharon Bio-Medicine Limited has informed the Exchange that�� Ms. Komal Mota has been appointed as a Company Secretary & Compliance Officer w.e.f�� January 08, 2019.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Revised Letter for '.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Dismissal of petition filed by erstwhile promoters in NCLAT'.

Sharon Bio-Medicine Limited has submitted to the Exchange, the financial results for the period ended September 30, 2018.

Sharon Bio-Medicine Limited has informed the Exchange regarding change in Corporate Office of the company.

Sharon Bio-Medicine Limited has informed the Exchange regarding Resignation of Ms Deepali Bhatia as Company Secretary & Compliance Officer of the company w.e.f. August 29, 2018.

Financial Results for the quarter ended on June 30, 2018.

Sharon Bio-Medicine Limited has submitted to the Exchange, the financial results for the period ended June 30, 2018.

The Exchange had sought clarification from Sharon Bio-Medicine Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed.

The Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not submitted within 30 minutes from end of board meeting. -2. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.

Sharon Bio-Medicine Limited has submitted to the Exchange, the financial results for the period ended March 31, 2018.

Financial Results for the quarter and year ended on March 31, 2018.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Appointment of Mr. Kaushik Banerjee as Chief Executive Officer of the company'.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Consent to Operate for API Plant Located at L-6, MIDC,Taloja, Dist.Raigad, Maharashtra-410208'.

Sharon Bio-Medicine Limited has informed the Exchange regarding Resignation of Ms Savita Gowda as Managing Director of the company w.e.f. March 30, 2018.

Sharon Bio-Medicine Limited has informed the Exchange regarding Resignation of Mr Lalit Misra as Executive Director of the company w.e.f. March 30, 2018.

SBICAP Trustee Company Limited has submitted to the Exchange a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'National Company Law Tribunal have Approved Resolution Plan submitted by Peter Beck & Partners. '.

SHARONBIO:The Exchange had sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 06-Mar-2018, regarding " Sharon Bio-Medicine Limited has informed the Exchange regarding 'Temporary Suspension of operations of API plant located at L-6, MIDC, Taloja, Dist. Raigad, Maharashtra 410208'.".On basis of above the Company is required to clarify following:1. Factory/unit where the strike/lock out takes place including reasons for such strike.<br>2. Estimated impact on the production/operations in case of strikes/lock outs;<br>3. Whether loss/damage covered by insuran

SHARONBIO:The Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 06-Mar-2018, regarding " Sharon Bio-Medicine Limited has informed the Exchange regarding 'Temporary Suspension of operations of API plant located at L-6, MIDC, Taloja, Dist. Raigad, Maharashtra �� 410208'.". On basis of above the Company is required to clarify following: 1. Factory/unit where the strike/lock out takes place including reasons for such strike.<br> 2. Estimated impact on the production/operations in case of strikes/lock outs;<br> 3. Whether loss/damage covered b

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Temporary Suspension of operations of API plant located at L-6, MIDC, Taloja, Dist. Raigad, Maharashtra �� 410208'.

Sharon Bio-Medicine Limited has submitted to the Exchange, the financial results for the period ended December 31, 2017.

Sharon Bio-Medicine Limited has submitted to the Exchange, the financial results for the period ended September 30, 2017.

Sharon Bio-Medicine Limited has submitted to the Exchange, the financial results for the period ended June 30, 2017.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Pursuant to Regulation 29(1) (a) of the SEBI (listing obligations and disclosure requirements) Regulations 2015, this is to inform you that Resolution Professional on Thursday, February 22, 2018 at 03.00 PM, will consider the Unaudited Financial Results of the Company for the Quarter ended on June 30, 2017, September 30, 2017 & December 31, 2017. '.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Submission of Resolution plan to NCLT on January 04, 2018.'.

The Exchange had sought clarification from Sharon Bio-Medicine Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results not submitted within 30 minutes from end of board meeting. -2. Financial results not submitted as per Schedule III to the Companies Act, 2013 -3. Financial results not submitted as per Ind-AS format. -4. Reconciliation of profit and loss not submitted. -5. Reconciliation of Equity not submitted

The Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not submitted within 30 minutes from end of board meeting. -2. Financial results not submitted as per Schedule III to the Companies Act, 2013 -3. Financial results not submitted as per Ind-AS format. -4. Reconciliation of profit and loss not submitted. -5. Reconciliation of Equity not submitted T

Sharon Bio-Medicine Limited has submitted to the Exchange, the financial results for the period ended 31-Mar-2017.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Notice for Financial Results for the Quarter ended on March 31st, 2017.'.

Sharon Bio-Medicine Limited has informed the Exchange regarding " Appointment of Secretarial and Cost Auditor".

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Intimation for extension of CIRP Process for 90 days with effect from October 08, 2017'.

Sharon Bio-Medicine Limited has informed the Exchange regarding Intimation for Extension of Annual General Meeting(AGM)

Significant increase in price has been observed in Sharon Bio-Medicine Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sharon Bio-Medicine Limited has submitted their response.

Significant increase in price has been observed in Sharon Bio-Medicine Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.

Sharon Bio-Medicine Limited has informed the Exchange regarding Financial results for the year ended March 31, 2017.

Sharon Bio-Medicine Limited has informed the Exchange the Intimation of initiation of Corporate Insolvency Resolution Process (CIRP) and appointment of Interim Resolution Professional (IRP).

Sharon Bio-Medicine Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on April 24, 2017 has took note of the following : Mr. Harish Palecanda and Dr. Nivedita Patil has tendered their resignation as an Independent Directors on the Board of the Company with effect from April 01, 2017.

SBICAP Trustee Company Ltd. has submitted to the Exchange a copy of disclosure under Regulation 30(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Sharon Bio-Medicine Limited has informed the Exchange regarding Change of address and contact details of M/s. Link Intime India Pvt. Ltd Registrar and Share Transfer Agent of the Company.

Sharon Bio-Medicine Limited has submitted to the Exchange, the financial results for the period ended 31-Dec-2016.

SHARONBIO: The Exchange had sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 14-Nov-2016, regarding "Sharon Bio-Medicine Limited has informed the Exchange that As per audited annual accounts the accumulated losses had exceeded the net worth of the company as on March 31, 2016 and therefore company has decided to make Reference to Board for Industrial and Financial Reconstruction (BIFR) in accordance with the provisions of Sick Industrial Companies (Special Provisions) Act, 1985.". On basis of above the Company is required to clarify following: 1. Reasons

SHARONBIO:The Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 14-Nov-2016, regarding "Sharon Bio-Medicine Limited has informed the Exchange that As per audited annual accounts the accumulated losses had exceeded the net worth of the company as on March 31, 2016 and therefore company has decided to make Reference to Board for Industrial and Financial Reconstruction (BIFR) in accordance with the provisions of Sick Industrial Companies (Special Provisions) Act, 1985.".On basis of above the Company is required to clarify following:1. Reasons fo

Sharon Bio-Medicine Limited has informed the Exchange that As per audited annual accounts the accumulated losses had exceeded the net worth of the company as on March 31, 2016 and therefore company has decided to make Reference to Board for Industrial and Financial Reconstruction (BIFR) in accordance with the provisions of Sick Industrial Companies (Special Provisions) Act, 1985.

Sharon Bio-Medicine Limited has submitted to the Exchange, the financial results for the period ended 30-Sep-2016.

Sharon Bio-Medicine Limited has submitted to the Exchange the details of voting results of the Annual General Meeting of the Company held on September 27, 2016 along with the Scrutinizer's Report

Sharon Bio-Medicine Limited has submitted to the Exchange a copy of Proceedings of the Annual General Meeting of the Company held on September 27, 2016.

Sharon Bio-Medicine Limited has informed the Exchange that Ms. Deepali Bhatia is appointed as a Company Secretary & Compliance officer w.e.f September 21, 2016.

The Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to recent news item captioned "USFDA approves Sharon Bio s Taloja API plant." The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sharon Bio-Medicine Limited has submitted their response.